Graft-Versus-Host Disease

Clonal hematopoiesis did not occur significantly more often among patients who received hematopoietic stem cell transplantation than their donors, according to findings of a correlative laboratory study.

Disparities in hematopoietic stem cell transplantation utilization for blood cancers have narrowed over time but still persist, according to study results.

Use of post-transplant cyclophosphamide prophylaxis to prevent graft-versus-host disease could greatly expand access to hematopoietic stem cell transplantation, according to results of a retrospective study.

Although similarities exist between ocular graft-versus-host disease and dry eye disease, more research is needed to improve diagnostic criteria and treatment, according to a review in Clinical & Experimental Ophthalmology.

In this video, Christine McMahon, MD, discusses the ACCESS study into post-transplant graft-versus-host disease, presented at ASCO Annual Meeting.

Editor’s note: This is the first in a series of five stories from ASCO Voices, a session during the 2024 ASCO Annual Meeting focused on the human side of oncology.

CHICAGO — Interim results from a phase 2 study showed positive survival outcomes for individuals who underwent peripheral blood stem cell transplantation for hematologic malignancies.

The amount of autologous and allogeneic hematopoietic stem cell transplants for hematologic disorders has increased over time in tandem with longer survival, according to results of an observational study.

Sumanta K. Pal, MD, FASCO, expressed a mix of emotions.